Search research articles
Contact Us
Filters
Showing results (31-40 of 106) with videos related to
Page
of 11
Sort By:
American Journal of Therapeutics
|
May 23, 2008
Rationale and design of the hemodynamic, echocardiographic and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure (HORIZON-HF) trial
John E A Blair, Cezar Macarie, Witold Ruzyllo, et al.
Journal of Cardiology
|
January 13, 2015
Computed tomography angiography for prediction of atrial fibrillation after coronary artery bypass grafting: proof of concept
Maksymilian P Opolski, Adam D Staruch, Mariusz Kusmierczyk, et al.
Cardiovascular Drugs and Therapy
|
May 27, 2004
Increasing awareness and perception of heart failure in Europe and improving care--rationale and design of the SHAPE Study
Willem Remme, Alessandro Boccanelli, Charles Cline, et al.
Journal of the American College of Cardiology
|
April 6, 2005
Direct intramyocardial plasmid vascular endothelial growth factor-A165 gene therapy in patients with stable severe angina pectoris A randomized double-blind placebo-controlled study: the Euroinject One trial
Jens Kastrup, Erik Jørgensen, Andreas Rück, et al.
Trials
|
June 21, 2013
Methods of creatine kinase-MB analysis to predict mortality in patients with myocardial infarction treated with reperfusion therapy
Renato D Lopes, Yuliya Lokhnygina, Victor Hasselblad, et al.
American Journal of Hypertension
|
October 2, 2007
Carotid intima-media thickness as a marker of cardiovascular risk in hypertensive patients with coronary artery disease
Tomasz Zielinski, Zofia Dzielinska, Andrzej Januszewicz, et al.
The American Journal of Cardiology
|
January 29, 2013
Infarct artery distribution and clinical outcomes in occluded artery trial subjects presenting with non-ST-segment elevation myocardial infarction (from the long-term follow-up of Occluded Artery Trial [OAT])
Venu Menon, Witold Ruzyllo, Antonio C Carvalho, et al.
Medical Science Monitor : International Medical Journal of Experimental and Clinical Research
|
September 2, 2009
Sodium level on admission and in-hospital outcomes of STEMI patients treated with primary angioplasty: the ANIN Myocardial Infarction Registry
Mariusz Klopotowski, Mariusz Kruk, Jakub Przyluski, et al.
Circulation
|
August 20, 2003
Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial
Christopher B Granger, Kenneth W Mahaffey, W Douglas Weaver, et al.
Circulation. Cardiovascular Quality and Outcomes
|
February 10, 2011
Mortality implications of primary percutaneous coronary intervention treatment delays: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction trial
Michael P Hudson, Paul W Armstrong, William W O'Neil, et al.
Page
of 11
Search research articles
Search
Showing results (31-40 of 106) with videos related to
Sort By:
Page
of 11
American Journal of Therapeutics
|
May 23, 2008
Rationale and design of the hemodynamic, echocardiographic and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure (HORIZON-HF) trial
John E A Blair, Cezar Macarie, Witold Ruzyllo, et al.
Journal of Cardiology
|
January 13, 2015
Computed tomography angiography for prediction of atrial fibrillation after coronary artery bypass grafting: proof of concept
Maksymilian P Opolski, Adam D Staruch, Mariusz Kusmierczyk, et al.
Cardiovascular Drugs and Therapy
|
May 27, 2004
Increasing awareness and perception of heart failure in Europe and improving care--rationale and design of the SHAPE Study
Willem Remme, Alessandro Boccanelli, Charles Cline, et al.
Journal of the American College of Cardiology
|
April 6, 2005
Direct intramyocardial plasmid vascular endothelial growth factor-A165 gene therapy in patients with stable severe angina pectoris A randomized double-blind placebo-controlled study: the Euroinject One trial
Jens Kastrup, Erik Jørgensen, Andreas Rück, et al.
Trials
|
June 21, 2013
Methods of creatine kinase-MB analysis to predict mortality in patients with myocardial infarction treated with reperfusion therapy
Renato D Lopes, Yuliya Lokhnygina, Victor Hasselblad, et al.
American Journal of Hypertension
|
October 2, 2007
Carotid intima-media thickness as a marker of cardiovascular risk in hypertensive patients with coronary artery disease
Tomasz Zielinski, Zofia Dzielinska, Andrzej Januszewicz, et al.
The American Journal of Cardiology
|
January 29, 2013
Infarct artery distribution and clinical outcomes in occluded artery trial subjects presenting with non-ST-segment elevation myocardial infarction (from the long-term follow-up of Occluded Artery Trial [OAT])
Venu Menon, Witold Ruzyllo, Antonio C Carvalho, et al.
Medical Science Monitor : International Medical Journal of Experimental and Clinical Research
|
September 2, 2009
Sodium level on admission and in-hospital outcomes of STEMI patients treated with primary angioplasty: the ANIN Myocardial Infarction Registry
Mariusz Klopotowski, Mariusz Kruk, Jakub Przyluski, et al.
Circulation
|
August 20, 2003
Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial
Christopher B Granger, Kenneth W Mahaffey, W Douglas Weaver, et al.
Circulation. Cardiovascular Quality and Outcomes
|
February 10, 2011
Mortality implications of primary percutaneous coronary intervention treatment delays: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction trial
Michael P Hudson, Paul W Armstrong, William W O'Neil, et al.
Page
of 11